Phase 3 Chronic Kidney Disease Trial, Recruiting NCT06337838 Sponsor: Hamilton Health Sciences Corporation Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 3 Chronic Kidney Disease Trial, Recruiting

NCT06337838
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who either have significantly reduced kidney function (based on a blood test result from the past 6 months), or have received dialysis (any type) within the last 7 days
  • People who are scheduled to have non-heart surgery — whether planned in advance, urgent, or emergency surgery
  • People who are expected to stay in hospital for at least one night after surgery
  • People aged 18 or older
  • People for whom written consent to take part in the BRACKETS-Pilot Trial has been obtained

Who may not be able to join:

  • People undergoing heart surgery
  • People undergoing brain surgery inside the skull
  • People having surgery to create or fix an arteriovenous fistula or graft (a connection made in the arm or leg for dialysis)
  • People for whom systemic use of tranexamic acid (TXA) or a similar medication (epsilon-aminocaproic acid) is already planned as a preventive measure
  • People with a known allergy or sensitivity to tranexamic acid (TXA)
  • People with a history of seizures
  • People who have had a stroke, heart attack, blood clot in an artery, deep vein clot, lung clot, or clotting in a dialysis fistula or graft within the past 90 days
  • People with a history of certain serious blood disorders, including thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, or antiphospholipid antibody syndrome
  • Women who are known to be pregnant or breastfeeding, or women who could become pregnant and do not have a negative pregnancy test recorded in the 7 days before surgery, and are not using effective contraception
  • People who have already taken part in the BRACKETS-Pilot Trial previously
  • People at hospitals where desmopressin (a second study medication) is not available (for the desmopressin part of the trial only)
  • People for whom desmopressin is already planned as a preventive treatment (for the desmopressin part of the trial only)
  • People whose most recent blood sodium level was below 130 mEq/L (for the desmopressin part of the trial only) (confirm with trial site)
  • People with a known or suspected bleeding disorder such as von Willebrand disease, hemophilia, or a platelet function disorder (for the desmopressin part of the trial only)
  • People with a known allergy or sensitivity to desmopressin (for the desmopressin part of the trial only)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pavel Roshanov, MC,MSc,FRCPC, Western University

Phone: 905-296-5754

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Hamilton Health Sciences Corporation
Registry
ClinicalTrials.gov
Start date
9 June 2025
Est. completion
1 February 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Rate of recruitment; Receipt of the allocated study drug within 1 hour before start of surgery for the tranexamic acid factorial; Receipt of the allocated study drug within 1 hour before start of surgery for the desmopressin factorial; Completion of 30-day follow-up

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov